Treatment of patients on oral anticoagulation who present with ACSSep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
Video navigation menu
- Case description: NSTEMI in a patient on direct oral anticoagulant with high bleeding risk 0:18
- Consider the higher bleeding risk when giving a combination of antiplatelet and anticoagulation therapy 1:44
- What to do with the NOAC during a procedure for ACS; and to bridge or not? 2:48
- What is the optimal treatment after stent placement - dual vs. triple therapy 6:29
- How was this case treated, and is that according to the 2017 update of the ESC DAPT guidelines? 13:25
- Conclusion 14:54
in recent years many studies have been published on the optimal duration of antiplatelet therapy in various patient groups undergoing PCI. This recording aims to highlight the practical implications of these study data for clinical practice.
Dr. Jur ten Berg - Cardiologist, St Antonius Hospital Nieuwegein, The Netherlands
Director of R&D Department of Cardiology, director of St Antonius Center for Platelet Function Research, Medical Director of Coronary Care Unit St Antonius Hospital.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding was provided by an unrestricted educational grant from Boehringer Ingelheim.
Jur ten Berg has received advisory / consulting fees from AstraZeneca, Eli Lilly, Daiichi Sankyo, the Medicines Company, Accumetrics and Boehringer-Ingelheim, BMS, and research grants of ZonMw, and AstraZeneca.